{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:08:19Z","timestamp":1789290499992,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p> Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical practice of migraine in recent years and to characterize patients potentially not managed well by current treatment options.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our study used data from the large claims database maintained by JMDC Inc. Patients with diagnosis of headache or migraine between January 1, 2018, and July 31, 2022, were defined as the\u00a0headache cohort, and those with migraine diagnosis and prescription of migraine treatments among the headache cohort were included in the migraine cohort. In the headache cohort, characteristics of medical facilities and status of imaging tests to distinguish secondary headache were examined. Treatment patterns and characteristics of patients potentially not managed well by acute\/preventive treatment were described in migraine cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the headache cohort, 989,514 patients were included with 57.0% females and mean age of 40.3\u00a0years; 77.0% patients visited clinics (with\u2009\u2264\u200919 bed capacities) for their primary diagnosis, and 30.3% patients underwent imaging tests (computed tomography and\/or magnetic resonance imaging). In the migraine cohort, 165,339 patients were included with 65.0% females and mean age of 38.8\u00a0years. In the migraine cohort, 95.6% received acute treatment while 20.8% received preventive treatment. Acetaminophen\/non-steroidal anti-inflammatory drugs were most common (54.8%) as the initial prescription for migraine treatment followed by triptan (51.4%). First treatment prescription included preventive treatment in 15.6%, while the proportion increased to 82.2% in the fourth treatment prescription. Among patients with more than 12\u00a0months of follow-up, 3.7% had prescription patterns suggestive of risk of medication-overuse headache, and these patients were characterized by a higher percentage of females and a higher prevalence of comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study revealed that approximately one-fifth of the patients with migraine visiting medical facilities use preventive drugs. The presence of potential patients at risk of medication-overuse headache and the role of clinics in migraine treatment were also described.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01722-5","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T13:02:51Z","timestamp":1707397371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan"],"prefix":"10.1186","volume":"25","author":[{"given":"Tsubasa","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"1722_CR1","doi-asserted-by":"publisher","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M et al (2022) Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 12:800605. https:\/\/doi.org\/10.3389\/fneur.2021.800605","DOI":"10.3389\/fneur.2021.800605"},{"issue":"1","key":"1722_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WF, Adams AM et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18(1):101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"issue":"1","key":"1722_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"issue":"1","key":"1722_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"11","key":"1722_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T (2020) Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open 10(11):e038987. https:\/\/doi.org\/10.1136\/bmjopen-2020-038987","journal-title":"BMJ Open"},{"key":"1722_CR6","doi-asserted-by":"publisher","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH et al (2022) Burden of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther 11(1):205\u2013222. https:\/\/doi.org\/10.1007\/s40120-021-00305-9","DOI":"10.1007\/s40120-021-00305-9"},{"issue":"1","key":"1722_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01439-3","volume":"23","author":"F Sakai","year":"2022","unstructured":"Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H et al (2022) A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J Headache Pain 23(1):70. https:\/\/doi.org\/10.1186\/s10194-022-01439-3","journal-title":"J Headache Pain"},{"issue":"11","key":"1722_CR8","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH et al (2022) Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther 39(11):5176\u20135190. https:\/\/doi.org\/10.1007\/s12325-022-02289-w","journal-title":"Adv Ther"},{"issue":"1","key":"1722_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T (2020) Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain 21(1):110. https:\/\/doi.org\/10.1186\/s10194-020-01180-9","journal-title":"J Headache Pain"},{"key":"1722_CR10","doi-asserted-by":"publisher","unstructured":"Khan J, Al Asoom LI, Al Sunni A, Rafique N, Latif R, Saif S et al (2021) Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother 139. https:\/\/doi.org\/10.1016\/j.biopha.2021.111557","DOI":"10.1016\/j.biopha.2021.111557"},{"key":"1722_CR11","unstructured":"Headache Clinical Practice Guideline Development Committee (2021) Clinical practice guideline for headache disorders 2021. Japanese Society of Neurology, Japanese Headache Society, and Japanese Society of Neurological Therapeutics (eds). Igaku-Shoin, Tokyo"},{"issue":"1","key":"1722_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K et al (2022) Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22(1):512. https:\/\/doi.org\/10.1186\/s12883-022-03041-1","journal-title":"BMC Neurol"},{"issue":"12","key":"1722_CR13","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F (2019) Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia 39(12):1518\u20131534. https:\/\/doi.org\/10.1177\/0333102419851855","journal-title":"Cephalalgia"},{"issue":"5","key":"1722_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/20494637221104292","volume":"16","author":"L Davis","year":"2022","unstructured":"Davis L, Torphy B (2022) Managing migraine on the frontline: identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care. Br J Pain 16(5):560\u2013573. https:\/\/doi.org\/10.1177\/20494637221104292","journal-title":"Br J Pain"},{"issue":"1","key":"1722_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24(1):23. https:\/\/doi.org\/10.1186\/s10194-023-01556-7","journal-title":"J Headache Pain"},{"key":"1722_CR16","doi-asserted-by":"publisher","unstructured":"Katsuki M, Yamagishi C, Matsumori Y, Koh A, Kawamura S, Kashiwagi K et al (2022) Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city\u2014Itoigawa study. Neurol Sci 43(6):3811\u20133822. https:\/\/doi.org\/10.1007\/s10072-021-05831-w","DOI":"10.1007\/s10072-021-05831-w"},{"issue":"2","key":"1722_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P (2023) Unmet needs in preventive treatment of migraine. Neurol Ther 12(2):337\u2013342. https:\/\/doi.org\/10.1007\/s40120-023-00438-z","journal-title":"Neurol Ther"},{"issue":"1","key":"1722_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20(1):68. https:\/\/doi.org\/10.1186\/s10194-019-1012-1","journal-title":"J Headache Pain"},{"key":"1722_CR19","unstructured":"JMDC (2023) JMDC claims database \u2013 JMDC Inc. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 19 Dec 2023"},{"key":"1722_CR20","unstructured":"Japanese Law Translation (2018) Medical care act: ensuring the medical care delivery system, Act No. 205 of July 30, 2018. https:\/\/www.japaneselawtranslation.go.jp\/en\/laws\/view\/4006\/en"},{"key":"1722_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10072-020-04643-8","volume":"41","author":"G Allais","year":"2020","unstructured":"Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C (2020) Gender-related differences in migraine. Neurol Sci 41:429\u2013436. https:\/\/doi.org\/10.1007\/s10072-020-04643-8","journal-title":"Neurol Sci"},{"issue":"4","key":"1722_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from Government Health studies. Headache 58(4):496\u2013505. https:\/\/doi.org\/10.1111\/head.13281","journal-title":"Headache"},{"key":"1722_CR23","doi-asserted-by":"publisher","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM et al (2021) Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin 37(11):1945\u20131955. https:\/\/doi.org\/10.1080\/03007995.2021.1971179","DOI":"10.1080\/03007995.2021.1971179"},{"issue":"1","key":"1722_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20(1):111. https:\/\/doi.org\/10.1186\/s10194-019-1062-4","journal-title":"J Headache Pain"},{"issue":"1","key":"1722_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y et al (2004) Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44(1):8\u201319. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04004.x","journal-title":"Headache"},{"issue":"1","key":"1722_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15(1):70. https:\/\/doi.org\/10.1007\/s11916-010-0157-z","journal-title":"Curr Pain Headache Rep"},{"key":"1722_CR27","doi-asserted-by":"publisher","unstructured":"Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK et al (2021) Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: results from the Assessment of TolerabiliTy and effectiveness in migrAINe patients using preventive treatment (ATTAIN) study. Headache 61(3):438\u2013454. https:\/\/doi.org\/10.1111\/head.14053","DOI":"10.1111\/head.14053"},{"issue":"1","key":"1722_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01623-z","volume":"24","author":"J Pascual","year":"2023","unstructured":"Pascual J, Panni T, Dell\u2019Agnello G, Gonderten S, Novick D, Evers S (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain 24(1):88. https:\/\/doi.org\/10.1186\/s10194-023-01623-z","journal-title":"J Headache Pain"},{"issue":"5","key":"1722_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ncn3.12322","volume":"7","author":"N Araki","year":"2019","unstructured":"Araki N, Takeshima T, Ando N, Iizuka T, Igarashi H, Ikeda Y et al (2019) Clinical practice guideline for chronic headache 2013. Neurol Clin Neurosci 7(5):231\u2013259. https:\/\/doi.org\/10.1111\/ncn3.12322","journal-title":"Neurol Clin Neurosci"},{"issue":"S1","key":"1722_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10072-019-03812-8","volume":"40","author":"MB Russell","year":"2019","unstructured":"Russell MB (2019) Epidemiology and management of medication-overuse headache in the general population. Neurol Sci 40(S1):23\u201326. https:\/\/doi.org\/10.1007\/s10072-019-03812-8","journal-title":"Neurol Sci"},{"issue":"3","key":"1722_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR et al (2021) Medication overuse and headache burden. Neurol Clin Pract 11(3):216\u2013226. https:\/\/doi.org\/10.1212\/CPJ.0000000000001037","journal-title":"Neurol Clin Pract"},{"key":"1722_CR32","unstructured":"Jasvinder C (2023) Migraine Headache Guidelines US Headache Consortium Pharmacologic treatment for episodic migraine prevention in adults. https:\/\/emedicine.medscape.com\/article\/1142556-guidelines?form=fpf"},{"issue":"5","key":"1722_CR33","doi-asserted-by":"publisher","first-page":"E187","DOI":"10.1503\/cmaj.221607","volume":"195","author":"V Tzankova","year":"2023","unstructured":"Tzankova V, Becker WJ, Chan TLH (2023) Pharmacologic prevention of migraine. CMAJ 195(5):E187\u2013E192. https:\/\/doi.org\/10.1503\/cmaj.221607","journal-title":"CMAJ"},{"issue":"4","key":"1722_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"CC Chiang","year":"2016","unstructured":"Chiang CC, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36(4):371\u2013386. https:\/\/doi.org\/10.1177\/0333102415593088","journal-title":"Cephalalgia"},{"issue":"1","key":"1722_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84. https:\/\/doi.org\/10.1186\/s10194-020-01151-0","journal-title":"J Headache Pain"},{"issue":"1","key":"1722_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"issue":"20","key":"1722_CR37","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse. Neurology 92(20):e2309\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01722-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T13:03:09Z","timestamp":1707397389000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01722-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"28 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board held by MINS (a specified nonprofit organization) on April 5, 2023 (647d88a729cc751d1e1ea75c.pdf (npo-mins.com). It was based on anonymized personal information following privacy laws, and obtaining informed consent from patients was not required. The principles outlined in the Declaration of Helsinki were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT is a consultant\/advisor and\/or serves on an advisory board for Pfizer, Eli Lilly, Otsuka, Amgen, and Teijin and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and grant from Pfizer and research funding from Eli Lilly and Tsumura outside the submitted work.\u00a0MI, TK, KT, and NY are employees of Pfizer Japan (Tokyo, Japan). MI, KT, and NY are shareholders of Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}